STLN · NASDAQ
Starling Oncology (STLN) Stock Price & Fundamentals
Starling Oncology (STLN) closed at $481.96 on Oct 9, 2026, up 0.48% from the previous close of $479.67.
Share price, past year
1Y +24.17%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $481.96 |
| Sep 30, 2026 | $472.24 |
| Aug 31, 2026 | $494.74 |
| Jul 31, 2026 | $493.38 |
| Jun 30, 2026 | $482.09 |
| May 29, 2026 | $448.82 |
| Apr 30, 2026 | $416.07 |
| Mar 31, 2026 | $422.78 |
| Feb 27, 2026 | $414.98 |
| Jan 30, 2026 | $402.02 |
| Dec 31, 2025 | $392.20 |
| Nov 28, 2025 | $388.84 |
| Oct 31, 2025 | $381.99 |
Key statistics
- Market cap
- $48.42B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.28
- Revenue (TTM)
- $587.24M
- Net income (TTM)
- −$36.29M
- Shares outstanding
- 100.5M
- Dividend yield
- —
- 52-week range
- $380.13 – $499.32
Starling Oncology's market cap is $48.42B, based on a share price of $481.96 and 100.5M shares outstanding as of Jun 30, 2026.
Financials
Starling Oncology reported revenue of $502.73M for fiscal 2025, up 27.79% from fiscal 2024.
Starling Oncology reported a net loss of $60.61M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 6 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $502.73M | +27.8% | −$60.61M | −12.1% | −$0.54 | −$27.79M |
| FY2024ended Dec 31, 2024 | $393.41M | +21.3% | −$64.66M | −16.4% | −$0.71 | −$30.33M |
| FY2023ended Dec 31, 2023 | $324.24M | +28.4% | −$83.07M | −25.6% | −$0.92 | −$40.88M |
| FY2022ended Dec 31, 2022 | $252.48M | +24.4% | $152.00K | 0.1% | −$0.21 | −$67.29M |
| FY2021ended Dec 31, 2021 | $203.00M | +8.3% | −$10.93M | −5.4% | −$0.16 | −$35.53M |
| FY2020ended Dec 31, 2020 | $187.52M | — | −$14.32M | −7.6% | −$0.24 | −$686.00K |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $161.28M | −$9.79M | −$0.08 |
| Q1 FY2026ended Mar 31, 2026 | $147.44M | −$2.49M | −$0.02 |
| Q4 FY2025ended Dec 31, 2025 | $141.96M | −$7.51M | −$0.04 |
| Q3 FY2025ended Sep 30, 2025 | $136.56M | −$16.50M | −$0.14 |
| Q2 FY2025ended Jun 30, 2025 | $119.80M | −$17.01M | −$0.15 |
| Q1 FY2025ended Mar 31, 2025 | $104.41M | −$19.59M | −$0.21 |
| Q4 FY2024ended Dec 31, 2024 | $100.27M | −$13.18M | −$0.14 |
| Q3 FY2024ended Sep 30, 2024 | $99.90M | −$16.11M | −$0.18 |
Company profile
- Name
- Starling Oncology, Inc.
- Ticker
- STLN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Services-Offices & Clinics of Doctors of Medicine
- Headquarters
- 18000 Studebaker Rd, Suite 800, Cerritos, CA 90703
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001799191
Recent SEC filings
- Sep 2, 2026
- Aug 21, 2026
- Aug 6, 2026
- Aug 6, 2026
- Aug 3, 2026
- Jul 7, 2026
- Jun 18, 2026
- May 22, 2026
Frequently asked questions
What is Starling Oncology's stock price?
Starling Oncology (STLN) closed at $481.96 on Oct 9, 2026, up 0.48% from the previous close of $479.67.
What is Starling Oncology's market cap?
Starling Oncology's market cap is $48.42B, based on a share price of $481.96 and 100.5M shares outstanding as of Jun 30, 2026.
How much revenue does Starling Oncology make?
Starling Oncology reported revenue of $502.73M for fiscal 2025, up 27.79% from fiscal 2024.
Does Starling Oncology pay a dividend?
Starling Oncology's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Starling Oncology, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures